E. Ramírez

Potential Role of Nuclear Factor κB in Diabetic Cardiomyopathy

J. Egido, Ó. Lorenzo, B. Picatoste, 2011, Mediators of inflammation.

Alteration of Energy Substrates and ROS Production in Diabetic Cardiomyopathy

J. Egido, Ó. Lorenzo, B. Picatoste, 2013, Mediators of inflammation.

Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

J. Egido, Ó. Lorenzo, C. Iborra, 2013, PloS one.

Correction: Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

J. Egido, Ó. Lorenzo, C. Iborra, 2013, PLoS ONE.

Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes

J. Egido, C. Barbas, A. Ferrarini, 2013, Cardiovascular Diabetology.

Targeting metabolic disturbance in the diabetic heart

J. Egido, Ó. Lorenzo, B. Picatoste, 2015, Cardiovascular Diabetology.

Targeting metabolic disturbance in the diabetic

J. Egido, Ó. Lorenzo, B. Picatoste, 2015 .

Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway

J. Egido, S. Mas, Ó. Lorenzo, 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.

Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking

J. Egido, Ó. Lorenzo, B. Picatoste, 2018, Cardiovascular Diabetology.